| dc.rights.license | CC-BY-NC-ND | |
| dc.contributor.advisor | Externe beoordelaar - External assesor, | |
| dc.contributor.author | Yilmaz, Habibe | |
| dc.date.accessioned | 2023-07-01T00:00:43Z | |
| dc.date.available | 2023-07-01T00:00:43Z | |
| dc.date.issued | 2023 | |
| dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/44073 | |
| dc.description.abstract | Introduction: The goal of this study was to develop a whole body physiological based pharmacokinetic-model (PBPK-model) to predict the tissue distribution of 18F-DCFPyL in patients with prostate cancer (PCa).
Method: The model was extended from a previously published PBPK-model describing PCa patients to predict the tissue distribution of 18F-DCFPyL. This model describes the tumors and organs at risks. The model was simulated and the results were compared to literature observations of patients with metastatic PCa.
Results: Our model adequately predicted the distribution of 18F-DCFPyL. Sensitivity analysis showed that the receptor densities, tumor flow and haematocrit had significant influence on the model outcome. The release and degradation of 18F-DCFPyL, and total organ volumes showed no significant influence on the outcome.
Discussion: The tumor flow, receptor densities and haematocrit should be measured in the future to accurately predict tissue distribution. The release and degradation of 18F-DCFPyL, and total organ volumes can be fixed on literature data.
Conclusion: The final PBPK-model was able to adequately predict tissue distribution of 18F-DCFPyL. | |
| dc.description.sponsorship | Utrecht University | |
| dc.language.iso | EN | |
| dc.subject | Het doel was om de weefselverdeling van 18F-DCFPyL in patiënten met prostaatkanker te voorspellen met behulp van een PBPK-model. 18F-DCFPyL is een PSMA-ligand en wordt momenteel gebruikt als tracer voor prostaatkanker. | |
| dc.title | PHYSIOLOGICALY BASED PHARMACOKINTEIC MODELLING OF 18F-DCFPYL TO PREDICT THE TISSUE DISTRIBUTION IN PATIENTS WITH PROSTATE CANCER | |
| dc.type.content | Master Thesis | |
| dc.rights.accessrights | Open Access | |
| dc.subject.keywords | PBPK-model; PSMA; Prostaatkanker; 18F-DCFPyL; Theranostics | |
| dc.subject.courseuu | Farmacie | |
| dc.thesis.id | 10217 | |
